Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22663602 | 0.93 | NPC1 (0.39) | NPC1SMN1; SMN2RAB9AHSD17B10L3MBTL1 | |
| SCHEMBL18481820 | 0.88 | NPC1 (0.36) | NPC1SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL18531475 | 0.82 | CNR2 (0.37) | TLR8 | |
| SCHEMBL20031029 | 0.81 | NPC1 (0.39) | NPC1SMN1; SMN2RAB9AHSD17B10TLR8 | |
| SCHEMBL21397925 | 0.81 | LTB4R (0.32) | L3MBTL1TSHR | |
| SCHEMBL18522970 | 0.81 | TLR8 (0.36) | TLR8 | |
| SCHEMBL23583995 | 0.80 | NPC1 (0.38) | NPC1SMN1; SMN2RAB9AHSD17B10TLR8 | |
| SCHEMBL18523069 | 0.79 | NPC1 (0.34) | NPC1SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL22930725 | 0.79 | NPC1 (0.40) | NPC1SMN1; SMN2RAB9AHSD17B10TLR8 | |
| SCHEMBL22930813 | 0.78 | NPC1 (0.39) | NPC1SMN1; SMN2RAB9AHSD17B10TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AP3M1, GPBAR1 | NPC1 1801/4885SMN1; SMN2 4259/4885RAB9A 893/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | NPC1 1801/4885SMN1; SMN2 4259/4885RAB9A 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.